Full-Time

Quality Assurance Laboratories Manager

Posted on 4/10/2026

Cooper Companies

Cooper Companies

201-500 employees

Global medical devices and vision care

No salary listed

Southampton, UK

In Person

Category
QA & Testing (1)
Required Skills
Six Sigma
Risk Management
Microbiology
Requirements
  • Minimum five years in the contact lens or medical device industry
  • Minimum of ten years in a Microbiology Laboratory setting
  • Experience in medical device industry, group direct reporting, and laboratory investigations
  • Experience in laboratory equipment (HPLC, GC, TOC, IR, UV, Incubators, autoclave, air sampler, etc.)
  • Experience in Quality Systems audits
  • Minimum of seven years in a Management/Supervisory experience
  • Minimum Batchelor of Science degree in Microbiology or Biological Sciences or related discipline and proven Microbiology background in Medical Device sector
  • Local travel between UK sites is necessary
  • International travel to other CooperVision Sites - no more than between 5% = 3 weeks per year
  • Strategy: Leverages professional expertise, external insights, customer & consumer needs to drive long range strategic thinking
  • Strategy: Develops distinctive strategies to achieve and exceed expected performance through process and our people
  • Strategy: Shares a vision that inspires and engages people
  • Strategy: Translates broad strategies into specific objectives, projects and action plans
  • Strategy: Aligns the organization to understand how every role supports the strategic priorities
  • Organisational Capability: Attracts and retains high calibre talent
  • Organisational Capability: Builds an inclusive, engaged culture that values diverse backgrounds and perspectives
  • Organisational Capability: Accurately appraises the strengths, weaknesses of others, providing coaching and constructive feedback
  • Organisational Capability: Inspires, motivates and develops team to achieve exceptional outcomes
  • Organisational Capability: Develops a talent pipeline to ensure successors and talent pools to support future needs
  • Results: Holds self and others accountable to achieve business results
  • Results: Sponsors and directs change while maintaining operating effectiveness
  • Results: Addresses root causes of issues and enable innovation and continuous improvement
  • Results: Establishes stretch goals, monitors results and budget demonstrating financial acumen
  • Results: Makes effective decisions by swiftly and critically considering risks, costs and benefits
  • Impact: Builds strong internal and external relationships based on honesty, candor, trust and respect
  • Impact: Understands the role/ interrelationships of each organizational function and demonstrates enterprise-wide thinking
  • Impact: Effectively manages priorities collaboratively across organizational groups to achieve best business outcome
  • Impact: Facilitates teamwork and honest communication across the organization
  • Impact: Listens, clarifies to understand intent, and skilfully shares information with others
  • Impact: Excellent communication skills, both verbal and written. Able to connect with clarity at all levels within the organisation
  • Mature Leadership: Open to learning, feedback and realistically appraises their own strengths and weaknesses
  • Mature Leadership: Maintains confidence, resilience and agility when challenged or in the face of adversity
  • Mature Leadership: Addresses issues directly with a fair and balanced approach with the company’s best interests in mind
  • Mature Leadership: Models’ high integrity and lives the organizational values
  • Mature Leadership: Recognizes high performance
  • Mature Leadership: Effective delegation and achievement of results through other individuals and teams
Responsibilities
  • To manage the QA Laboratories departments of Microbiology, Autoclave, and Materials testing
  • To ensure all incoming materials are tested and accepted in accordance with our specifications and medical device regulations and standards including ISO13485, MDD, MDR, FDA QSR
  • To train Microbiology laboratory technicians ensuring all safety procedures are followed and that the required training is completed and recorded in a timely manner
  • The organisation of the workload to maintain the required level of routine monitoring and non-routine work to support Business Unit Projects
  • Validation of the test methods used in the laboratory and for other microbiologically related procedures such as the effectiveness of disinfection
  • As process owner for QA Laboratories and Microbiology, you will be required to support external audits by our notified bodies and health authorities
  • Processing and approval of Materials and Microbiology data in a timely manner to support the business production and release targets
  • Engineering Change Control: Lead and participate in the planning, preparation and execution of Engineering Changes Orders (ECO). In addition to provide support to Business unit projects with Risk Assessments and Engineering studies
  • Risk Management: Lead and participate on risk management teams
  • CAPA/NCR: Leading CAPA investigations and being involved in CAPA investigation teams, Completing CAPA Investigation reports and identifying / implementing Corrections, Corrective Actions and Preventive Actions as appropriate.Raising NCRs as required and reviewing NCRs to ensure relevant information is inputted and the correct product disposition is implemented
  • Understanding and applying the Six Sigma methodology including Define, Measure, Analyse, Improve and Control and participate on Six Sigma improvement projects
  • Use of aseptic technique for sampling of water, solution systems and un-autoclaved lenses and testing for bioburden
  • Testing the above according to relevant test methods, recording results and maintaining trend analysis
  • Performing environmental monitoring by laying settle plates, air sampling and monitoring of personnel in the wet production areas, recording results and maintaining trend analysis
  • To review the above results and investigate any identified areas of microbiological concern/contamination
  • Identification of isolates as required
  • Review of autoclave validation reports to ensure compliance to the respective Testing Monographs
  • Training of personnel in GMP and Introduction to Microbiology for working in Areas of Specified Environmental Cleanliness (ASECs) and sterilisation theory training in the absence of the Autoclave Validation Specialist
  • Responsible for setting departmental budget and reforecasting when required
  • Any other related duties connected with the Company’s business
  • Local travel between UK sites is necessary
  • International travel to other CooperVision Sites - no more than between 5% = 3 weeks per year

Cooper Companies operates in two main areas: CooperVision and CooperSurgical. CooperVision makes a wide range of contact lenses to correct vision, supported by product development, manufacturing, and global distribution. CooperSurgical offers medical devices, fertility, and genomic products for women’s health, covering care from contraception through advanced reproductive treatments, with a vertically integrated model that controls research, development, manufacturing, and distribution. Compared with competitors, the company combines vision care and women’s health in one group and maintains end-to-end control of its product lifecycle, enabling integrated supply and service delivery to healthcare providers and patients worldwide. Its goal is to improve health outcomes for people through accessible contact lenses and comprehensive women’s health products and services, across the globe.

Company Size

201-500

Company Stage

IPO

Headquarters

Pleasanton, California

Founded

1958

Your Connections

People at Cooper Companies who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Premium lens adoption drove Q4 and Q1 2026 growth and market-share gains.
  • EMEA revenue reached $289.7 million in April 2026, supporting international expansion.
  • Management raised 2026 guidance, reflecting improving margins and stronger free-cash-flow generation.

What critics are saying

  • Japan's legacy hydrogel lens declines continue to pressure CooperVision growth.
  • Asia Pacific revenue missed expectations, signaling weaker execution in a key region.
  • Fertility demand and reimbursement cycles can disrupt CooperSurgical's revenue and margin support.

What makes Cooper Companies unique

  • Two-unit model spans vision care and women's health across CooperVision and CooperSurgical.
  • CooperVision leads soft contact lenses, including premium MyDay and MyDay MiSight products.
  • Global footprint reaches over 130 countries, with more than 15,000 employees.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

Performance Bonus

Health Insurance

401(k) Retirement Plan

Life Insurance

Wellness Program

Professional Development Budget

Company News

Oregon Capital Insider
May 4th, 2026
CooperCompanies appoints Paul Keel to its Board of Directors.

CooperCompanies appoints Paul Keel to its Board of Directors. GlobeNewswire | CooperCompanies Yesterday at 1:15pm PDT SAN RAMON, Calif., May 04, 2026 (GLOBE NEWSWIRE) - CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today that its Board of Directors has appointed Paul Keel as an independent director, effective July 1, 2026. Mr. Keel has also been appointed to serve on the Audit Committee when he joins the Board. "We are delighted to welcome Paul to our Board as a new Director," said Colleen Jay, Chair of the Board of CooperCompanies. "His experience as a CEO in the medical device sector, along with a successful track record of leading complex global operations, will be a significant asset as Cooper continues to execute its strategy and create long-term value for patients, customers, and shareholders." Mr. Keel has served as President and Chief Executive Officer of Envista Holdings Corporation (NYSE: NVST), a global specialty medical technology company, since 2024. Prior to joining Envista, Mr. Keel served as CEO of Smiths Group plc (LON: SMIN), a diversified global industrial technology company and FTSE constituent, from 2021 to 2024. Earlier, he spent 16 years at 3M, serving in various leadership roles, including Group President of 3M Consumer Business, President of 3M Medical, President of 3M Unitek, SVP of Manufacturing & Supply Chain, and SVP of Marketing, Sales & Business Development. Mr. Keel's career also includes roles at General Mills, General Electric, Norwest Equity Partners, and McKinsey & Company. He holds an MBA from Harvard Business School and a BA in Economics from Carleton College. About CooperCompanies CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com. Forward-Looking Statements This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to the Company's efforts to enhance long-term shareholder value, plans, strategies, future actions, and other statements of which are other than statements of historical fact, are forward-looking. Forward-looking statements necessarily depend on assumptions, data, or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Statements regarding future events and performance and contain words such as "expects" and similar words or phrases. A wide range of factors could materially affect future developments, including, but not limited to, uncertainties related to market conditions and other factors set forth in its other filings with the United States Securities and Exchange Commission, including its most recent Annual Report on Form 10-K. These risks and uncertainties may cause actual future results or actions to be materially different than those expressed in such forward-looking statements. Oregon Capital Insider do not intend, or undertake any duty, to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Kim Duncan Vice President, Investor Relations and Risk Management 925-460-3663 This is a paid placement. For further inquiries, please contact GlobeNewswire directly.

Yahoo Finance
Apr 8th, 2026
Cooper Companies shares drop 17% in 3 months amid valuation debate at $13.7B market cap

Cooper Companies has raised $120 million in a Series C round, valuing the healthcare company at $1.45 billion, as shares face recent pressure with declines of 9% over the past month and roughly 17% over three months. The company operates two main businesses: CooperVision, generating revenue of $2.79 billion from contact lenses, and CooperSurgical, contributing $1.36 billion from women's and family health products. Total annual revenue reached $4.15 billion with net income of $401.4 million. Recent analysis suggests the stock may be 24.1% undervalued at its current price of $69.66, with a fair value estimate of $91.80. Management projects approximately $2 billion in free cash flow over the next three years as capital expenditure cycles wind down.

Yahoo Finance
Mar 25th, 2026
CooperCompanies Q4 revenue hits $1.02B, raises full-year earnings guidance

CooperCompanies reported Q4 revenues of $1.02 billion, up 6.2% year on year, meeting analysts' expectations. The medical devices manufacturer, which focuses on vision care and women's health products, delivered an impressive beat on full-year earnings per share guidance, though organic revenue was in line with estimates. The company raised both earnings and free cash flow guidance following strong profitability and cash generation. Operating margins exceeded expectations due to synergies from last year's reorganisation. President and CEO Al White highlighted momentum from product launches, including the premium MyDay portfolio and early traction from MyDay MiSight. Across the medical devices and supplies sector, six tracked companies reported mixed Q4 results, with revenues collectively beating consensus estimates by 1.9%. Share prices have declined 9.5% on average since earnings announcements.

Yahoo Finance
Mar 17th, 2026
Cooper Companies down 21% from 52-week high despite beating Q1 earnings estimates

Cooper Companies, a California-based medical devices manufacturer, has declined 12.5% over the past 52 weeks, underperforming the Dow Jones Industrial Average's 13.2% gain during the same period. The company, valued at $13.9 billion, has fallen 20.9% from its December 2025 peak of $89.83. Shares dropped 2.2% on 5 March following mixed Q1 2026 results. Whilst revenue rose 6% year-over-year to $1 billion and adjusted earnings per share increased 20% to $1.10, both beating estimates, investors focussed on weak organic revenue growth and challenges in the Asia Pacific region. The stock has traded below its 200-day and 50-day moving averages since early March. Despite the decline, analysts maintain a "Moderate Buy" rating with a mean price target of $90.81, suggesting 27.8% upside potential.

Yahoo Finance
Mar 12th, 2026
Needham raises Cooper Companies price target to $101, maintains buy rating after strong Q1 results

Needham raised its price target on The Cooper Companies (NASDAQ: COO) to $101 from $99, maintaining a Buy rating. The firm cited solid first-quarter results, improving end markets and operating efficiencies supporting margin expansion. Barclays also increased its target to $103 from $98 with an Overweight rating, noting improving sequential growth in Vision and Surgical segments offsetting declines in older hydrogel products in Japan. Cooper Companies reported first-quarter non-GAAP earnings per share of $1.10, beating the $1.03 consensus estimate, with revenue of $1.024 billion versus $1.02 billion expected. CEO Al White highlighted growth in the MyDay portfolio and benefits from last year's reorganisation. The company develops and markets products for contact lens wearers through its CooperVision and CooperSurgical segments.

INACTIVE